Oct 15, 2025 03:42AM Citizens Downgrades Astria Therapeutics (ATXS) to Market Perform

Oct 15, 2025 03:42AM Citizens Downgrades Astria Therapeutics (ATXS) to Market Perform

Oct 14, 2025 04:34PM Oppenheimer Downgrades Astria Therapeutics (ATXS) to Perform

Oct 14, 2025 06:55AM Astria Therapeutics, Inc. (ATXS) Halted, News Pending

Oct 9, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

Oct 3, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

Sep 18, 2025 06:57AM Astria Therapeutics (ATXS) PT Raised to $20 at H.C. Wainwright

Aug 13, 2025 04:05AM Astria Therapeutics (ATXS) PT Raised to $26 at Citizens JMP

Aug 12, 2025 05:46PM Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 8c

Aug 6, 2025 08:01AM Astria Therapeutics signs $32 million Japan licensing deal with Kaken

Jun 16, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

Jun 13, 2025 07:00AM Astria Therapeutics, Inc. (ATXS) Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart

May 29, 2025 04:05AM Citizens JMP Reiterates Market Outperform Rating on Astria Therapeutics (ATXS)

May 14, 2025 09:00AM Cantor Fitzgerald Reiterates Overweight Rating on Astria Therapeutics (ATXS)

May 14, 2025 04:09AM Astria Therapeutics (ATXS) PT Lowered to $25 at Citizens JMP

May 13, 2025 04:11PM Astria Therapeutics, Inc. (ATXS) Misses Q1 EPS by 13c

May 1, 2025 08:03AM Astria Therapeutics (ATXS) Announces Publication of Navenibart Phase 1a Healthy Subject Results

Apr 29, 2025 06:33AM Cantor Fitzgerald Starts Editas Medicine (ATXS) at Overweight

Apr 23, 2025 04:15AM Citizens JMP Reiterates Market Outperform Rating on Astria Therapeutics (ATXS)

Mar 3, 2025 04:32AM Citizens JMP Reiterates Market Outperform Rating on Astria Therapeutics (ATXS)

Feb 18, 2025 04:12AM JMP Securities Reiterates Market Outperform Rating on Astria Therapeutics (ATXS)

Jan 31, 2025 04:43AM JMP Securities Initiates Astria Therapeutics (ATXS) at Market Outperform

Jan 31, 2025 03:29AM JMP Securities Starts Astria Therapeutics (ATXS) at Market Outperform

Jan 24, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

Jan 13, 2025 08:03AM Astria Therapeutics (ATXS) Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Dec 10, 2024 08:08AM Astria Therapeutics (ATXS) Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Nov 20, 2024 07:39AM TD Cowen Reiterates Buy Rating on Astria Therapeutics (ATXS)

Nov 13, 2024 04:11PM Astria Therapeutics, Inc. (ATXS) Reports In-Line Q3 EPS

Oct 16, 2024 08:05AM Astria Therapeutics (ATXS): EC Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema

Sep 30, 2024 08:01AM Astria Therapeutics (ATXS) Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Sep 27, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

Sep 25, 2024 11:07AM TD Cowen Reiterates Buy Rating on Astria Therapeutics (ATXS)

Aug 13, 2024 09:29AM TD Cowen Reiterates Buy Rating on Astria Therapeutics (ATXS)

Aug 13, 2024 07:51AM Astria Therapeutics (ATXS) PT Raised to $26 at Oppenheimer

Aug 13, 2024 06:04AM H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)

Aug 12, 2024 04:21PM Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 6c

Aug 12, 2024 04:01PM Astria Therapeutics (ATXS) Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema

Jul 29, 2024 05:29AM TD Cowen Starts Astria Therapeutics (ATXS) at Buy